


Benchmark No. 7 Inotrope Administration



**British Association of
Neuroscience Nurses**



Benchmark No. 7

Inotrope Administration

Copyright © 2007 British Association of Neuroscience Nurses. All rights reserved.

First PDF edition printed 2017 in the United Kingdom (available online)

A catalogue record for this book is available from the British Library.

ISBN 978-1-911059-07-3

No part of this book shall be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information retrieval system without written permission of the publisher.

Published by the British Association of Neuroscience Nurses

For more copies of this book, please email: info@bann.org.uk

Designed and Set by the British Association of Neuroscience Nurses

www.bann.org.uk

Printed in the United Kingdom

Although every precaution has been taken in the preparation of this publication, the publisher and authors assume no responsibility for errors or omissions. Neither is any liability assumed for damages resulting from the use of this information contained



History

The Neuroscience Nursing Benchmarking Group (NNBG) was established in the 1990's as a result of increasing concerns over inconsistencies in practices as part of a subsidiary of BANN. The group aims to improve on the quality of care by comparing and sharing practice with each other, and set explicit standards for comparison of current practice against the ideal standard. The group is committed to searching for the best evidence related to specific areas of neuroscience practice. Membership of the group consists of representatives from neuroscience units within the UK and Ireland, together with educational colleagues from both the NHS/HSC and Higher Educational Institutes. The group is further subdivided into regions and this benchmark was developed by the North East group of the NNBG in 2007.

In 2016, the NNBG consolidated back into BANN and further information about NNBG can be found on the BANN website www.BANN.org.uk.

BANN would like to acknowledge the leadership and significant contribution made by the NNBG, and all its contributors, to neuroscience nursing over the years.

Benchmark No.7 Inotrope Administration

Key Points

- Patients are nursed in a level 2/3 facility
 - The effect of these drugs vary greatly so close observation is essential
- Continuous monitoring of ECG
- Blood pressure via an arterial line providing a continuous recording
- Parameters are set for drug delivery and therapeutic goals by medical staff and documented on individual Care Plans
 - It is important that parameters for drug delivery and therapeutic goals are clearly discussed and recorded
 - Equally, any changes in vital signs and subsequent drug delivery are clearly documented so that the response or effect of the drug can be assessed easily
- Evidence based guidelines are available as a key way of improving and achieving a consistent quality of care
- Staff receive training in managing a patient with Inotropes and competency in Inotrope administration is completed
 - Maintaining a stable cardiovascular status will for many patients depend on continuous drug delivery
 - Nurses need to be familiar with and ensure that the correct equipment is working order is used
 - Adequate supplies of the drug need to be accessible and prepared in good time
 - All infusions must be checked at nurse/shift handover
 - Drug calculations are complex and nurses must be familiar with and understand calculations required to work out the doses
- Education is available, including guidelines for changing syringes and drug calculations. This is reviewed every two years

FACTOR 1 – Documentation – Assessment and Implementation of Care

STATEMENT OF BEST PRACTICE	POOR ← LEVEL OF ACHIEVEMENT → EXCELLENT
1.0 Decision to use Inotropes should be based on clinical needs and documented in patient's Care Plan [Davies 2001].	
1.1 The Care Plan meets individual needs of the patient and should be regularly re-evaluated	
1.2 Baseline observations should be recorded prior to commencement of inotrope therapy	
1.3 Parameters to be set for the Inotrope therapy rate and patient blood pressure (regularly reviewed) and documented in Care Plan.[Davies 2001]	
1.4 Patient blood pressure must be continuously monitored and recorded hourly on the patient's record/chart [Juarez 2005].	
1.5 All documentation has been reviewed within the last 2 years	

FACTOR 2 – Protocol

STATEMENT OF BEST PRACTICE		POOR ←	LEVEL OF ACHIEVEMENT	→ EXCELLENT
2.0	The Protocol is research evidence based [Juarez 2005]			
2.1	<p>The Protocol will include the following FACTORS:</p> <ul style="list-style-type: none"> ▪ Criteria for commencement of therapy ▪ Procedure for administration ▪ Guidelines for double pumping ▪ CVP level as a baseline recording ▪ Calculation of drug dosage ▪ Frequency of line changing ▪ Invasive monitoring equipment required for Inotrope therapy administration (including continuous ECG monitoring) [Crisp 2002]. ▪ Dedicated line for Inotrope therapy - appropriately labelled ▪ Inotrope should ALWAYS be administered via a central line ▪ Identification of syringes 			

FACTOR 3 – Education


STATEMENT OF BEST PRACTICE	POOR ← LEVEL OF ACHIEVEMENT → EXCELLENT
3.0 A structured training programme for staff is available and includes.	
3.1 Professional accountability issues related to Inotrope therapy [Juarez 2005]	
3.2 Safe practice in changing lines and labelling. Reducing and increasing patient Inotrope therapy. Importance of single use line with Inotropes and the reason flushes are not given [Quinn 2000].	
3.3 Anatomy and physiology [Marieb 2001].	
3.4 Application of Inotrope Protocol and documentation process	
3.5 Checking patient Inotrope infusion at handover period [NMC 2002, Juarez 2005]	

FACTOR 4 – Patient Information

STATEMENT OF BEST PRACTICE		POOR ←	LEVEL OF ACHIEVEMENT	→ EXCELLENT
4.0	Patient / carer informed of procedure [NMC 2004, DOH 2001]			
4.1	Information given to patient / carer recorded in patient documentation. [NMC 2004]			
4.2	Information provided to be supplied by evidenced of good practice. [NMC 2004]			

References

- Amoore J, Adamson L [2003] Infusion devices: Characteristic Limitations and Risk Management. Nursing Standard Vol. 17, No 28, 45-52
- Crisp H [2002] Minimising the Risks: Safe Administration of Inotropes Drug Infusions in Critical Care. Nursing in Critical Care Vol 17, No 6, 283-289
- Davies N [2000] Cardiac Care in: Sheppard M, Wright M. Principles and Practice in High Dependency Nursing. Balliere Tindall London
- Juarez P [2005] Safe Administration of IV Infusions: part 2, Dilators and Inotropic Agents: The do's and don'ts. American Journal of Nursing Vol. 105, 10, October 2005, 72-78
- Morrice A et al [2004] Practical considerations in administration of intravenous vasoactive drugs in the critical care setting. Intensive and Critical Care Nursing, Vol. 20, 183-189
- Nursing & Midwifery Council [2002] Code of Professional Conduct, London
- Quinn C [2000] Infusion devices: Risks/Functions and Management. Nursing Standard, Vol. 14. No. 26, 35-43
- Shulman R et al [eds] [1998] UCL Hospitals Injectable Drug Administration of Medicines.
- Trim J, Roe J [2004] Practical considerations in the administration of intravenous vasoactive drugs in the critical care setting: The double pumping or piggyback technique – Part one. Intensive and Critical Care Nursing 20, 3, 153-160
- Nursing & Midwifery Council (2002) Guidelines for the administration of medicines. UMC, London



**Benchmark No. 7
Inotrope Administration**

ISBN 9781911059073



9 781911 059073